Patents Assigned to The Rockfeller University
-
Patent number: 11497797Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.Type: GrantFiled: March 29, 2022Date of Patent: November 15, 2022Assignee: The Rockfeller UniversityInventors: David Bikard, Luciano Marraffini
-
Publication number: 20190274619Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.Type: ApplicationFiled: May 17, 2019Publication date: September 12, 2019Applicant: The Rockfeller UniversityInventors: Daniel GAREAU, Justin Martin
-
Patent number: 9005579Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: GrantFiled: January 5, 2011Date of Patent: April 14, 2015Assignees: Contrafect Corporation, The Rockfeller UniversityInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
-
Patent number: 7521241Abstract: A method is provided of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide in said plant cell which polypeptide binds to the target DNA and modulates transcription of the coding sequence.Type: GrantFiled: September 12, 2007Date of Patent: April 21, 2009Assignees: Gendaq Limited, The Rockfeller UniversityInventors: Yen Choo, Christopher Graeme Ullman, Nam-Hai Chua, Juan Pablo Sanchez
-
Patent number: 7432052Abstract: Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.Type: GrantFiled: November 15, 2002Date of Patent: October 7, 2008Assignees: The Rockfeller University, Duke University, Emory UniversityInventors: Stephen T. Warren, Victoria Brown-Kennerly, Peng Jin, Stephanie Ceman, Robert B. Darnell, Jennifer C. Darnell, Jack D. Keene, Scott A. Tenenbaum
-
Patent number: 7381705Abstract: The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses.Type: GrantFiled: September 26, 2005Date of Patent: June 3, 2008Assignees: The Administrators Of The Tulane Educational Fund, The Rockfeller UniversityInventors: Robert F. Garry, Jane A. McKeating
-
Patent number: 7339039Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted With interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN? and IFN?. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.Type: GrantFiled: June 7, 2001Date of Patent: March 4, 2008Assignee: The Rockfeller UniversityInventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
-
Patent number: 7033759Abstract: Provided herein are variant alleles of a gene encoding a kappa opioid receptor, along with cloning vectors for replicating such variant alleles, and expressing vectors for expressing the variant alleles to produce variant kappa opioid receptors.Type: GrantFiled: July 13, 2001Date of Patent: April 25, 2006Assignee: The Rockfeller UniversityInventors: Mary Jeanne Kreek, Vadim Yuferov, Karl Steven LaForge
-
Patent number: 6395482Abstract: Variations in the DNA sequence of the human proline dehydrogenase gene (PRODH) which correlate to an increased susceptibility to, or presence of schizophrenia or a disease or disorder related thereto, such as obsessive compulsive disorder (OCD), bipolar disorder (BP), or major depressive disorder (MDD) are provided, along with assays to diagnosing schizophrenia or a disease or disorder related thereto, and evaluating potential drugs or agents for using in treating such diseases or disorders.Type: GrantFiled: March 26, 1999Date of Patent: May 28, 2002Assignee: The Rockfeller UniversityInventors: Maria Karayiorgou, Joseph A. Gogos
-
Patent number: 6369030Abstract: Histone acetyltransferase inhibitors, especially those that are differentiate between p300 and PCAF histone acetyltransferase; also therapeutic processes comprising their administration to humans.Type: GrantFiled: November 29, 1999Date of Patent: April 9, 2002Assignee: The Rockfeller UniversityInventors: Philip A. Cole, Raymond E. Soccio, Ontario D. Lau, Ehab M. Khalil, Tapas K. Kundu, Robert G. Roeder
-
Patent number: 6346605Abstract: A novel component of the TRAF (TNF Receptor Associated Factor) signaling complex, designated TRIP (TRAF Interacting Protein) which associates with the TNFR2 or CD30 signaling complex through its interaction with the TRAF2 protein and influences signals responsible for cell activation, cell proliferation and cell death.Type: GrantFiled: March 31, 1998Date of Patent: February 12, 2002Assignee: The Rockfeller UniversityInventors: Soo Young Lee, Yongwon Choi
-
Patent number: 6309853Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention.Type: GrantFiled: June 7, 1995Date of Patent: October 30, 2001Assignee: The Rockfeller UniversityInventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
-
Patent number: 6297356Abstract: The present invention relates to a novel nucleotide sequence encoding a telomeric protein which binds a repeat region of telomeric sequences, and to the protein encoded thereby. Also included within the invention are expression vectors for the production of the telomeric protein and host cells transformed with the nucleotide sequence. In addition, antibodies, probes and antagonists specific for the telomeric protein are contemplated. Methods of identifying antagonists of the telomeric protein, diagnostic methods of identifying the telomeric protein in a sample, and therapeutic uses of the telomeric protein, particularly in the treatment of aging and cancer, are also contemplated.Type: GrantFiled: February 4, 1998Date of Patent: October 2, 2001Assignee: The Rockfeller UniversityInventors: Titia DeLange, Dominique Broccoli, Agata Smogorzenska
-
Patent number: 6291428Abstract: Peptides are provided with the properties of enhancing the migration and adhesion of bone-forming cells to a substrate, useful for promoting bone mineralization and osseointegration in the healing of, for example, orthopedic surgical procedures.Type: GrantFiled: December 20, 1999Date of Patent: September 18, 2001Assignees: The Hospital for Special Surgery, The Rockfeller UniversityInventors: William B. Macaulay, Elizabeth Merrifield, Adele Boskey
-
Patent number: 6143566Abstract: A simple method for modifying genes in a recombination deficient host cell is disclosed. Such modifications include generating insertion, deletions, substitutions, and/or point mutations at any chosen site in the independent origin based cloning vector. The modified gene can be contained in an independent origin based cloning vector that is used to introduce a modified heterologous gene into a cell. Such a modified vector may be used in the production of a germline transmitted transgenic animal, or in gene targeting protocols in eukaryotic cells.Type: GrantFiled: June 23, 1997Date of Patent: November 7, 2000Assignee: The Rockfeller UniversityInventors: Nathaniel Heintz, Peter Model, Xiangdong W. Yang
-
Patent number: 6139831Abstract: Apparatus and method for immobilizing molecules, particularly biomolecules such as DNA, RNA, proteins, lipids, carbohydrates, or hormones onto a substrate such as glass or silica; patterns of immobilization can be made resulting in addressable, discrete arrays of molecules on a substrate, having applications in bioelectronics, DNA hybridization assays, drug assays, etc.Type: GrantFiled: May 28, 1998Date of Patent: October 31, 2000Assignee: The Rockfeller UniversityInventors: Ganaganor Visweswara Shivashankar, Albert J. Libchaber
-
Patent number: 6124448Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignee: The Rockfeller UniversityInventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca, Margherita Maffei
-
Patent number: 6124118Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN.alpha. and IFN.gamma..Type: GrantFiled: October 10, 1997Date of Patent: September 26, 2000Assignee: The Rockfeller UniversityInventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
-
Patent number: 6106844Abstract: The present invention is directed to immunogenic peptides from vespid antigen 5. These immunogenic peptides can be used in immunotherapy for vespid venom allergic individuals. The present invention is thus directed to T cell epitopes of vespid antigen 5 that can anergize T cell responses in sensitive individuals.Type: GrantFiled: August 6, 1998Date of Patent: August 22, 2000Assignee: The Rockfeller UniversityInventor: Te Piao King
-
Patent number: 6057129Abstract: The present invention provides isolated nucleic acids and/or recombinant DNA molecules that encode the clock protein DOUBLETIME. The present invention further provides both isolated and/or recombinant DOUBLETIME. In addition, the present invention provides antibodies to DOUBLETIME. Methods of using the nucleic acids, proteins and antibodies of the present invention, including as therapeutics are also provided.Type: GrantFiled: June 19, 1998Date of Patent: May 2, 2000Assignee: The Rockfeller UniversityInventors: Michael W. Young, Brian Kloss, Justin Blau, Jeffrey Price